Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis Sees 4% Compound Annual Growth in Sales Through 2026

12/02/2021 | 07:04am EST


ę MT Newswires 2021
All news about NOVARTIS AG
01/15Factbox-GSK's consumer health business
RE
01/14NOVARTIS AG : Morgan Stanley gives a Neutral rating
MD
01/12Novartis to File for COVID-19 Drug's Emergency Use in US by February Amid Omicron Surge
MT
01/12NOVARTIS AG : JP Morgan reiterates its Sell rating
MD
01/11Novartis Mulls Oncology, Cardiovascular Treatment Expansion
MT
01/10GLOBAL MARKETS LIVE : Meta, Goldman Sachs, Novartis, Tesla, Boeing...
01/10Novartis-Molecular Partners COVID drug could be approved in weeks
RE
01/10Molecular Partners Shares Rise 19% After Ensovibep Trial Meets Primary Endpoint
DJ
01/10Novartis Still Undecided On Future Of Sandoz
MT
01/10Novartis CEO says no decision has been taken on Sandoz
RE
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 52 087 M - -
Net income 2021 24 243 M - -
Net Debt 2021 8 534 M - -
P/E ratio 2021 8,32x
Yield 2021 3,64%
Capitalization 201 B 202 B -
EV / Sales 2021 4,03x
EV / Sales 2022 3,89x
Nbr of Employees 108 000
Free-Float -
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 90,03 $
Average target price 98,17 $
Spread / Average Target 9,05%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG2.54%201 737
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317